baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Zealand Pharma A/S/ DK0060257814 /

11/06/2024 09:41:10	Chg. -6.75	Volume	Bid09:41:36	Ask09:41:36	High	Low
650.50DKK	-1.03%	3,131 Turnover: 945,389.25	649.50Bid Size: 14	651.50Ask Size: 102	655.00	643.00

GlobeNewswire 07/06 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improveme...

GlobeNewswire 07/06 Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...

GlobeNewswire 06/06 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial ...

GlobeNewswire 31/05 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...

GlobeNewswire 29/05 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

GlobeNewswire 23/05 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low ...

GlobeNewswire 16/05 Zealand Pharma Announces Financial Results for the First Quarter of 2024

GlobeNewswire 09/05 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...

GlobeNewswire 20/03 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...

GlobeNewswire 01/03 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference

GlobeNewswire 27/02 Zealand Pharma Announces Financial Results for the Full Year 2023

TeleTrader 26/02 Zealand Pharma soars 30% on positive weight-loss drug results

GlobeNewswire 26/02 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...

GlobeNewswire 26/02 Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...

GlobeNewswire 20/02 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financia...

GlobeNewswire 19/01 Zealand Pharma major shareholder announcement: J O Hambro Capital Management

GlobeNewswire 17/01 Zealand Pharma major shareholder announcement: J O Hambro Capital Management

GlobeNewswire 12/01 Zealand Pharma completes registration of capital increase

GlobeNewswire 10/01 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC

GlobeNewswire 08/01 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion

GlobeNewswire 02/01 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on Janua...

GlobeNewswire 23/12/2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyp...

GlobeNewswire 22/12/2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome

GlobeNewswire 22/12/2023 Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank

GlobeNewswire 04/12/2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5

Zealand Pharma A/S/ DK0060257814 /

If you wish to receive reply to your feedback, please provide your email address.